Yes, you should offer Wegovy (semaglutide 2.4 mg) to this patient with BMI >25 and ASCVD.
Wegovy is FDA-approved specifically for reducing major adverse cardiovascular events (cardiovascular death, non-fatal MI, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight, making this an evidence-based indication for your patient 1.
Primary Evidence Base
The SELECT trial definitively established cardiovascular benefit in exactly this patient population. In 17,604 patients with preexisting cardiovascular disease and BMI ≥27 (without diabetes), semaglutide 2.4 mg reduced the composite primary endpoint by 20% (HR 0.80,95% CI 0.72-0.90, p<0.001) over a mean follow-up of 39.8 months 2. This translates to 6.5% vs 8.0% event rates—a clinically meaningful absolute risk reduction of 1.5%.
The cardiovascular benefit appears independent of glycemic status. Even in patients who were normoglycemic at baseline (HbA1c <5.7%) or who had no HbA1c improvement during treatment, semaglutide still reduced cardiovascular events 3. This means the mechanism extends beyond glucose control alone.
Guideline Support
The 2022 AGA guidelines conditionally recommend semaglutide 2.4 mg with lifestyle modifications for adults with obesity or overweight with weight-related complications 4. While this predates the SELECT trial's cardiovascular indication, the guideline notes that GLP-1 receptor agonists decrease CVD event risk in adults with overweight/obesity without diabetes, and specifically highlights semaglutide's superior efficacy over other anti-obesity medications 5, 4.
The 2023 JAMA obesity management review emphasizes that the SELECT study showed cardiovascular benefit in patients with CVD and BMI ≥27 without diabetes, with a hazard ratio of 0.80 5. This aligns perfectly with your patient's profile.
Practical Implementation
Start with 0.25 mg weekly and titrate up to the target dose of 2.4 mg over 16-20 weeks 1. This gradual escalation mitigates the most common adverse effects—nausea and vomiting—which occur due to delayed gastric emptying 1.
Key monitoring points:
- Gastrointestinal symptoms: Most common reason for discontinuation (16.6% vs 8.2% placebo) 2
- Gallbladder disease and pancreatitis: Known class effects requiring clinical vigilance 4
- Long-term commitment: The half-life is approximately 1 week, and weight regain occurs after discontinuation (mean 11.6% weight regain after stopping) 5, so this is a chronic therapy
Patient Selection Refinements
Your patient fits the ideal profile if they have:
- BMI ≥27 kg/m² (the SELECT trial threshold) 2
- Established ASCVD (prior MI, stroke, or peripheral artery disease) 1, 2
- No diabetes (different indication pathway if diabetic)
The benefit extends across subgroups including those with heart failure (both preserved and reduced ejection fraction), with HR 0.72 for MACE in heart failure patients 6. Real-world data from 2026 shows even greater risk reduction (29% for rMACE-3) compared to tirzepatide in this population 7.
Critical Caveats
Avoid phentermine-topiramate in patients with established cardiovascular disease—the AGA guidelines explicitly state it should be avoided in this population 4. This makes semaglutide the preferred agent for your patient.
Do not combine with other GLP-1 receptor agonists or semaglutide-containing products 1. Check that the patient isn't already on Ozempic (semaglutide for diabetes) or other GLP-1 RAs.
Counsel about teratogenicity concerns: While semaglutide itself has less direct teratogenic data than topiramate, discuss contraception with women of childbearing potential given the weight loss and metabolic effects.
Reimbursement Reality
The FDA cardiovascular indication (approved based on SELECT) strengthens the case for insurance coverage in patients with established ASCVD and BMI ≥27 1. Frame the prescription as cardiovascular risk reduction, not just weight management, to optimize approval likelihood.
The medication requires chronic use—benefits persist only with continued therapy, and the steady-state concentration takes approximately 4-5 weeks to achieve 1. Set expectations for long-term treatment from the outset.